VXRT’s earning reports are in and currently in phase 2 of their clinical trials for their Covid vaccine pill. Vaxart also rose 46.73% from its 52-week low and is up 20.67% year to date. While Covid numbers in the US are trending south, the rest of the world is still being ravaged. Do you buy, sell, or hold? Are we still bullish or are we now bearish? Let’s break it down in today’s episode of Money Talk Sundayz.

Thanks for tuning in to Money Talk Sundayz. I’m your investment Bro Stevie Bee. It’s been a few weeks since I last covered Vaxart so today we’re going to circle back and see what’s up with our favorite oral vaccine candidate stock. Hit that like button on your way in and let’s get started.

During the recent session, Vaxart Inc. (NASDAQ:VXRT)’s traded shares were 1.68 million, with the beta value of the company hitting 0.24. At the last check today, the stock’s price was $6.57, reflecting an intraday loss of -4.64% or -$0.32. The 52-week high for the VXRT share is $24.90, that puts it down -279.0 from that peak though still a striking 46.73% gain since the share price plummeted to a 52-week low of $3.50. The company’s market capitalization is $887.57M, and the average trade volume was 4.52 million shares over the past three months.

Vaxart Inc. (VXRT) is currently still a recommended Buy from analysts.

Vaxart Inc. (VXRT) registered a -4.64% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.64% in intraday trading to $6.57 this Thursday, 11/04/21, hitting a weekly high. The stock’s 5-day price performance is -0.14%, and it has moved by -2.96% in 30 days. Based on these gigs, the overall price performance for the year is 34.57%.

Per the CEO, VXRT’s oral vaccine candidate “is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”

Vaxart recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants. This has allowed the Company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials started and planned to start this year, and to begin manufacturing vaccines for its upcoming norovirus Phase II trials.

Vaxart scaled up its research, quality and manufacturing capabilities, increasing its R&D employee headcount by more than 35% during the quarter.

Vaxart named Dr. James F. Cummings as its Chief Medical Officer. Dr. Cummings is a board-certified infectious disease physician with extensive experience in vaccine, drug and diagnostics development, and will help guide the Company’s development of its vaccines.